Says Bilchick, This study adds to our knowledge of the effect of these GLP-1 receptor agonists on reducing morbidity, mortality, and now, in this large study, reducing incident atrial fibrillation over the long term. More research is still needed, especially regarding how different GLP-1 medications, doses, and treatment durations affect weight loss, inflammation, glucose control, Afib risk, and long-term cardiovascular health
Say it out loud
Visceral fat matters for several reasons: Higher metabolic risk: Visceral fat is strongly associated with insulin resistance, Type 2 diabetes, cardiovascular disease, and fatty liver disease
The key is gradual dosing, electrolyte monitoring, and coordination with your cardiologist